Public Services and Procurement Minister Anita Anand stated right now that Canada is able to deploy a new COVID vaccine from Johnson & Johnson’s pharmaceutical division, Janssen, as soon as it receives regulatory approval from Health Canada — however she could not say what number of photographs will be accessible within the coming weeks.
The U.S. Food and Drug Administration’s vaccines and associated organic merchandise advisory committee will meet Friday to review the scientific trial information for this vaccine. A last U.S. choice on issuing emergency use authorization (EUA) may comply with as early as this weekend.
The identical FDA committee met in early December to review Pfizer’s vaccine and, a day later, the EUA was issued. Later that month, the FDA committee met to review the Moderna vaccine and an EUA was granted the following day.
Canada has ordered 10 million doses from Johnson & Johnson with choices for as much as 28 million extra, if vital. Most of these photographs are anticipated to reach by the tip of September.
Anand stated she had a dialog with executives from Johnson & Johnson final week “to ensure we are on target in terms of those deliveries and to press them on when precisely those deliveries would be arriving in Canada.”
Drug makers ‘reluctant’ to set deadlines with out approvals: Anand
Asked if she is aware of what number of doses will be delivered within the second quarter of this yr — when Canada’s vaccination marketing campaign is predicted to ramp up — Anand stated “that is a negotiation that we are currently engaged in and I will provide information relating to the details of those deliveries as soon as I have them.”
Anand stated it is “too early” to say what number of doses, if any, Canada will obtain within the April via June interval.
She stated vaccine producers are “reluctant” to supply agency supply dates with a regulatory review course of nonetheless pending, however she has assured Johnson & Johnson that “Canada is ready for the deployment and distribution of vaccines” and that these photographs will be put to make use of straight away.
Last month, the corporate confirmed with U.S. officers that it was on monitor to ship 100 million doses to the American market by the tip of June.
The firm has signed offers to produce photographs at plants in Indiana, Maryland and Michigan within the U.S. and other services in Europe with a view to meet its contractual obligations.
“We’re very confident and on track to meet all of our commitments,” the corporate’s CFO, Joseph Wolk, informed CNBC in January.
The firm’s Canadian division has not but provided comparable assurances.
“It is premature to address the supply specifics of our vaccine candidate,” a spokesperson for the corporate stated in an e-mail to CBC News.
“Janssen is continuing to work with Health Canada to complete the rolling submission process,” the spokesperson stated.
The Johnson & Johnson product, which requires just one shot as an alternative of two just like the Moderna and Pfizer vaccines, can be a lot simpler for public health officers to manage because it stays steady in a typical fridge for months.
Unlike these two photographs, which are based mostly on mRNA technlogy, the Johnson & Johnson product makes use of a extra typical viral vector load vaccine know-how. Millions of people may develop some type of antibody safety in opposition to COVID-19 with only a single dose.
In U.S. scientific trials, the product was discovered to be 72 per cent efficient in stopping moderate-to-severe cases of COVID-19.
Importantly, the product additionally demonstrated full safety in opposition to COVID-19-related hospitalization and demise, 28 days post-vaccination.
The firm has stated the single-shot vaccine has “the potential to significantly reduce the burden of severe disease.”